These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 8251888)
1. An overview of some studies of chronic myelogenous leukemia: biological-clinical observations and viewing the disease as a chaotic system. Preisler H; Raza A Leuk Lymphoma; 1993; 11 Suppl 1():145-50. PubMed ID: 8251888 [TBL] [Abstract][Full Text] [Related]
2. Proliferative advantage rather than classical drug resistance as the cause of treatment failure in chronic myelogenous leukemia. Preisler HD; Raza A; Baccarani M Leuk Lymphoma; 1993; 11 Suppl 1():303-6. PubMed ID: 7504547 [TBL] [Abstract][Full Text] [Related]
3. Cell biology of CML--a model linking the chronic and terminal phases. Gordon MY Leuk Lymphoma; 1993; 11 Suppl 1():93-100. PubMed ID: 8251924 [TBL] [Abstract][Full Text] [Related]
4. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia. Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222 [TBL] [Abstract][Full Text] [Related]
6. Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients. Martinelli G; Zaccaria A; Farabegoli P; Buzzi M; Testoni N; Bragliani M; Panzica G; Tura S Leuk Lymphoma; 1993; 11 Suppl 1():51-6. PubMed ID: 8251917 [TBL] [Abstract][Full Text] [Related]
7. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related]
8. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance. Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282 [TBL] [Abstract][Full Text] [Related]
9. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients. Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454 [TBL] [Abstract][Full Text] [Related]
10. Disease progression in a murine model of bcr/abl leukemogenesis. van Etten RA Leuk Lymphoma; 1993; 11 Suppl 1():239-42. PubMed ID: 8251903 [TBL] [Abstract][Full Text] [Related]
11. Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia. Simanovsky M; Berlinsky S; Sinai P; Leiba M; Nagler A; Galski H Differentiation; 2008 Oct; 76(8):908-22. PubMed ID: 18452548 [TBL] [Abstract][Full Text] [Related]
12. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597 [TBL] [Abstract][Full Text] [Related]
13. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Skórski T; Szczylik C; Malaguarnera L; Calabretta B Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439 [TBL] [Abstract][Full Text] [Related]
15. CML: mechanisms of disease initiation and progression. Wetzler M; Talpaz M; Estrov Z; Kurzrock R Leuk Lymphoma; 1993; 11 Suppl 1():47-50. PubMed ID: 8251916 [TBL] [Abstract][Full Text] [Related]
16. Abnormal regulation of the myc gene in myeloid leukemia. Gopal V; Kadam P; Preisler H; Hulette B; Li YQ; Steele P; Freeman J; Banavali S Med Oncol Tumor Pharmacother; 1992; 9(3):139-47. PubMed ID: 1341325 [TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of a CML patient with a long duration of chronic phase before and after lymphoid blast crisis. Price CM; Foadi MD; Morgan GJ; Wiedemann LM Leukemia; 1990 Jun; 4(6):455-7. PubMed ID: 2359347 [TBL] [Abstract][Full Text] [Related]
18. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy. Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ; PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013 [TBL] [Abstract][Full Text] [Related]
19. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia. Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306 [TBL] [Abstract][Full Text] [Related]
20. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Beran M; Pisa P; O'Brien S; Kurzrock R; Siciliano M; Cork A; Andersson BS; Kohli V; Kantarjian H Cancer Res; 1993 Aug; 53(15):3603-10. PubMed ID: 8339266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]